Cravedi et al., COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium, American Journal of Transplantation, doi:10.1111/ajt.16185
Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, p = 0.17. Subject to confounding by indication.
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted confounding by indication likely.
Abstract: Received: 18 May 2020
|
|
Revised: 24 June 2020
Accepted: 25 June 2020
DOI: 10.1111/ajt.16185
B R I E F C O M M U N I C AT I O N
COVID-19 and kidney transplantation: Results from the
TANGO International Transplant Consortium
Paolo Cravedi1
| Suraj S. Mothi2 | Yorg Azzi3 | Meredith Haverly1 | Samira S. Farouk4
|
5
5
1
4
María J. Pérez-Sáez
| Maria D. Redondo-Pachón | Barbara Murphy | Sander Florman |
2
Laura G. Cyrino | Monica Grafals6 | Sandheep Venkataraman6 | Xingxing S. Cheng7
|
7
8
9
10
Aileen X. Wang | Gianluigi Zaza
| Andrea Ranghino | Lucrezia Furian |
11
Joaquin Manrique | Umberto Maggiore12 | Ilaria Gandolfini12 | Nikhil Agrawal13 |
| Leonardo V. Riella14,15
Het Patel13 | Enver Akalin3
1
Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
2
Schuster Transplantation Research Center, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts
3
Division of Nephrology, Montefiore Medical Center Transplant Center, Albert Einstein College of Medicine, Bronx, New York
4
Recanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York
5
Servicio de Nefrología, Hospital del Mar, Barcelona, Spain
6
Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
7
Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Stanford, Massachusetts
8
Renal Unit, Department of Medicine, University Hospital of Verona, Verona, Italy
9
SOD Nefrologia, Dialisi e Trapianto Rene, AOU Ospedali Riuniti, Ancona, Italy
10
Kidney and Pancreas Transplantation Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy
11
Nephrology Service, Complejo Hospitalario de Navarra, Pamplona, Spain
12
Dipartimento di Medicina e Chirurgia, Università di Parma, UO Nefrologia, Azienda Ospedaliera-Universitaria Parma, Parma, Italy
13
Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
14
Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
15
Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts
Correspondence
Paolo Cravedi
Email: paolo.cravedi@mssm.edu
Leonardo V. Riella
Email: lriella@mgh.harvard.edu
Kidney transplant recipients may be at a high risk of developing critical coronavirus
disease 2019 (COVID-19) illness due to chronic immunosuppression and comorbidities. We identified hospitalized adult kidney transplant recipients at 12 transplant
centers in the United States, Italy, and Spain who tested positive for COVID-19. Clinical
presentation, laboratory values, immunosuppression, and treatment strategies were
reviewed, and predictors of poor clinical outcomes were determined through multivariable analyses. Among 9845 kidney transplant recipients across centers, 144 were
hospitalized due to COVID-19 during the 9-week study period. Of the 144 patients,
66% were male with a mean age of 60 (±12) years, and 40% were Hispanic and 25%
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; IL, interleukin; MMF,
mycophenolate mofetil; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
Enver Akalin and Leonardo V. Riella are co-senior authors.
Paolo Cravedi and Suraj Sarvode Mothi..
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.